Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | ALUNBRIG versus alectinib ALTA 3 | ALK+ Advanced NSCLC | Phase 3 | Ongoing | oral | Oncology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Mobocertinib EXCLAIM-2 | NSCLC with EGFR exon 20 insertion mutations | Phase 3 | Withdrawn | Oral | Oncology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Osavampator (NBI-1065845) - (SAVITRI) | Major depressive disorder | Phase 3 | Ongoing | Oral | Psychiatric |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Mezagitamab (TAK-079) - (TAK-079-1004) | Primary Immune Thrombocytopenia | Phase 3 | Enrollment Initiation | Intravenous | Hematology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Alofisel (darvadstrocel) - (ADMIRE-CD II) | Complex Crohn's Perianal Fistulas (CPF) | Phase 3 | Data Released | Intralesional | Gastroenterology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Vedolizumab - (EARNEST) | Pouchitis | Phase 3 | Data Released | Intravenous | Gastroenterology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Vedolizumab - (GRAPHITE) | Acute Graft-Versus-Host Disease (aGvHD) in patients allo-HSCT | Phase 3 | Data Released | Intravenous | Immunosuppressant |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Fazirsiran (ARO-AAT) - (SEQUOIA) | Alpha-1 Liver Disease | Phase 2/3 | Ongoing | Subcutaneous | Genetic Disorder |
